VERICI DX PLC

Regulatory Filings • Jan 5, 2022

National Storage Mechanism | Additional information

RNS Number : 4292X

Verici Dx PLC

05 January 2022

Verici Dx plc

("Verici Dx" or the "Company") 

Verici Dx and Illumina demonstrate the clinical utility of Illumina's newly launched data platforms for analytics

Readiness for launch, accelerated by Illumina Connected Analytics (ICA), represents an important milestone in the path to commercialization of Verici Dx's lead products

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces a pioneering collaboration with Illumina, Inc. (NASDAQ: ILMN), to expedite the operational launch of data analysis processing and predictive artificial intelligence component of Verici Dx's products using early access to ICA, Illumina's new software platform for operationalized secondary analysis with an advanced data science environment.

Verici Dx's underlying technology is based upon artificial intelligence assisted transcriptomic analysis of proprietary RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, resulting in rejection and graft failure beginning pre-transplant and following to late-stage.

ICA will provide Verici Dx with the ability to process large datasets, allowing for AI-enabled RNA signature testing to be clinically available at a more robust level than has been previously possible. ICA also enables Verici Dx to build custom workflows in a secure and compliant environment. With streamlined querying of large data sets, ICA supports Verici Dx's leading-edge technology and provides a framework for future data science discovery. ICA allows the integration of Illumina sequencers and software in a cloud-based environment and is accessible globally enabling further expansion and collaboration opportunities for Verici Dx.

Having access to this state-of-the-art platform provides a substantial enhancement to Verici Dx's data management and interrogation capabilities and bolsters its ability to develop highly predictive future products. It will also enable Verici Dx to stay at the forefront of improving patient outcomes.

Susan Tousi, Chief Commercial Officer of Illumina, said: "We are pleased to collaborate with Verici Dx to provide a platform for them to advance their sequencing analytical methodologies for organ transplant tests. Looking towards the future of Illumina's software portfolio, Illumina Connected Analytics is the foundation upon which we are building to get data-driven answers."

Sara Barrington, CEO of Verici Dx, said: "We are delighted to announce the successful operational launch of the Verici Dx data analysis processing and predictive artificial intelligence components of our clinical products as inaugural users of Illumina's new ICA platform. Our leading-edge science depends on the ability to process vast amounts of data into meaningful and interpretable segments, and we believe there is no better tool to support us in this than ICA. We are very proud to be an early-access user of this tool in the commercial space from a world-class provider and leader in servicing the global sequencing market.

"This milestone represents a key step in the readiness of both the near-term launches of our flagship Clarava™ and Tuteva™ products, as well as the long-term strategy for building the computational data analytics tools that will power the future of Verici Dx's data science. We look forward to updating the market with our further progress towards commercialization in due course."

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: 020 7496 3000
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Walbrook PR Limited	Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen	Mob: 07980 541 893 / 07502 558 258

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The company also has a mission to accelerate the pace of innovation by research using the fully characterized data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBIMPTMTBMBTT